Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gang
A 19-year-old British tourist who was subjected to a horrific sex attack in Majorca 'was gang-raped2024-05-21ACWF Donates Masks to Iran, Japan and Republic of Korea
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21ACWF's Suggestions and Proposals Focus on Needs of Women, Children
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21ACWF Calls on Women, Families to Stop Wasting Food, Promote Thrifty Living
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
WASHINGTON (AP) — The Supreme Court on Monday declined, for now, to hear a challenge to a Maryland l2024-05-21ACWF Calls for Building Green Families Online
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment